Navigating Zepbound Availability: What Doses Are Experiencing Shortages?

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The honest answer is that the national tirzepatide shortage that dominated 2023 and 2024 is over, so the premise of the question has changed: there is no longer a set of Zepbound doses sitting on a federal shortage list. The FDA resolved the tirzepatide shortage and then wound down the enforcement discretion that had allowed compounders to make copies — the deadline for state-licensed 503A pharmacies was February 18, 2025, and for registered outsourcing facilities March 19, 2025. The semaglutide equivalents followed on April 22 and May 22, 2025. What people run into today is something different and more local: a particular strength not on the shelf at a particular pharmacy on a particular week. That is a distribution and stocking problem, not a national shortage, and it is worth knowing how to tell the two apart.

A Shortage Is a Specific Regulatory Status

"Shortage" is not a synonym for "my pharmacy didn't have it." Under federal law the FDA maintains a drug shortage database, and a product is listed there when the agency determines that demand or projected demand nationally exceeds available supply. Individual presentations — a specific strength, in a specific container, from a specific manufacturer — are listed separately, which is why during the tirzepatide shortage some doses were flagged as having limited availability while others were unaffected.

The authoritative place to check any drug's current status is the FDA's own drug shortage database, not a telehealth company's marketing page and not a forum thread. The database is updated as manufacturers report supply changes, and it distinguishes between "currently in shortage," "resolved," and discontinued presentations. If a Zepbound strength were genuinely constrained nationally, that is where it would appear.

What Actually Happened, in Order

Demand for incretin therapies outran manufacturing capacity soon after tirzepatide reached the market, and the FDA's shortage listing triggered a period during which compounding pharmacies could lawfully prepare copies of an otherwise commercially available drug. Manufacturing capacity then expanded, the shortage was resolved, and the legal basis for compounding copies fell away on the dates above.

The wind-down was staged deliberately so patients were not cut off mid-treatment. It is the reason the compounded GLP-1 market looks different in 2026 than it did in 2024, and the reason any page still describing an ongoing tirzepatide shortage is working from stale information.

Why Availability Still Varies by Dose

Even with a resolved national shortage, dose-level availability at the counter is genuinely uneven, and there are structural reasons for it. Zepbound is supplied across a wide strength range — 2.5 mg through 15 mg — in single-dose pens, single-dose vials and multi-dose pen presentations. Each strength and each container type is a separate stock-keeping item, manufactured, allocated and ordered independently.

Demand across those strengths is also lopsided and moves over time. Because the labeled regimen starts at 2.5 mg once weekly for four weeks and escalates in 2.5 mg increments no faster than every four weeks, large groups of patients pass through the lower strengths quickly and then concentrate in the maintenance strengths. A pharmacy that stocks to last quarter's pattern can be short of one strength while overstocked on another, with no national shortage involved at all.

Distribution adds a third layer. Independent pharmacies, chains and mail-order dispensers order on different cycles from different wholesalers. Two pharmacies four blocks apart can have entirely different answers on the same afternoon.

Know Which Tirzepatide Product You Are Asking About

Two FDA-approved products contain tirzepatide, and they are not interchangeable at the pharmacy. Zepbound is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity, per the Zepbound prescribing information. Mounjaro is the same molecule approved only for glycemic control in type 2 diabetes.

This matters for availability questions because the two brands are separate products with separate supply chains, separate NDC codes and separate insurance rules. A pharmacy having one says nothing about whether it has the other, and a prescription cannot simply be filled with whichever is in stock.

Where Compounded Tirzepatide Fits Now

Compounded tirzepatide has not disappeared, but its legal footing changed when the shortage resolved. It is dispensed by licensed 503A compounding pharmacies pursuant to a prescription written for an individual patient. It is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed.

The FDA has been explicit about the risks it has seen in this space, warning that it has received adverse event reports after patients used compounded semaglutide and that some compounders were using salt forms that are different active ingredients than those in the approved drugs. Those cautions are about sourcing and pharmacy quality, which is exactly why the identity and licensure of the dispensing pharmacy is the thing to ask about. A compounded preparation is never a generic version of an approved brand, because no approved tirzepatide product has an approved generic.

What to Do When Your Strength Is Not in Stock

The productive move is a conversation, not a substitution. Your prescriber decides whether any change to your regimen is appropriate; your pharmacy can tell you whether the item is on backorder from their wholesaler, when their next delivery lands, and whether another location in the same system has it. Neither question is one to answer for yourself by adjusting what you take.

It is also worth checking the FDA database before assuming a national problem. In most cases in 2026 the answer is that supply exists and the gap is logistical — which usually means the fix is a phone call rather than a change in therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Which Zepbound doses are currently in shortage?

The national tirzepatide shortage has been resolved, so no Zepbound strength sits on the FDA shortage list on that basis today. Availability at an individual pharmacy can still vary by strength and container type because each is ordered and stocked separately. The authoritative place to confirm current status for any presentation is the FDA drug shortage database, which lists products by strength and manufacturer.

When did compounders have to stop making tirzepatide copies?

After the FDA resolved the tirzepatide shortage, the enforcement discretion that had permitted compounded copies wound down on staged deadlines: February 18, 2025 for state-licensed 503A compounding pharmacies and March 19, 2025 for registered outsourcing facilities. The parallel semaglutide deadlines were April 22 and May 22, 2025. The staging was designed so patients were not interrupted mid-treatment.

Why does my pharmacy have one strength but not another?

Each strength and container type is a separate stock item ordered independently from wholesalers on different cycles. Demand also shifts across strengths over time, because the labeled regimen starts at 2.5 mg once weekly and escalates in 2.5 mg increments no more often than every four weeks, so patients concentrate in maintenance strengths. Two nearby pharmacies can therefore give different answers the same day.

Can I substitute Mounjaro if Zepbound is unavailable?

No. Zepbound and Mounjaro contain the same molecule but are separate FDA-approved products with different indications, different labeling and separate supply chains. Zepbound is approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity; Mounjaro is approved only for glycemic control in type 2 diabetes. A prescription cannot be swapped between them at the counter.

Is compounded tirzepatide a substitute for Zepbound?

It is a different regulatory category, not a generic. Compounded tirzepatide is prepared by a licensed pharmacy pursuant to a prescription for an individual patient, and the FDA does not review compounded preparations for safety, effectiveness or quality before marketing. The FDA has reported adverse events after use of compounded semaglutide and has warned that some compounders used salt forms that differ from the active ingredient in approved drugs.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.